Article concludes “Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.” (NEJM, articles in press) Click here to read full text.
News You Can Use
Society for ambulatory anesthesia consensus statement on perioperative blood glucose management in diabetic patients undergoing ambulatory surgeryby jmiller on October 12, 2015
“Optimal evidence-based perioperative blood glucose control in patients undergoing ambulatory surgical procedures remains controversial. Therefore, the Society for Ambulatory Anesthesia has developed a consensus statement on perioperative glycemic management in patients undergoing ambulatory surgery. It was revealed that there is insufficient evidence to provide strong evidence, recommendations were based on general principles of blood glucose control in diabetics, drug pharmacology, and data from inpatient surgical population, as well as clinical experience and judgment. (Anesth Analg ) Click here to read full text.
Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents.by jmiller on September 9, 2015
Article concludes: The ginkgo biloba is an effective and safe complementary tratment for ADHD. It resulted in significant increase in overall clinical treatment response. (Complementary Therapies in Clinical Pracitice, August) Click here to read full-text.
Article concludes: “The evidence for the viability of bone-targeted pharmacotherapy in preventing hip fracture and other clinical fragility fractures is mainly limited to women aged 65-80 years with osteoporosis, whereas the proof of hip fracture-preventing efficacy in women over 80 years of age and in men at all ages is meagre or absent. Further, the antihip fracture efficacy shown in clinical trials is absent in real-life studies. Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events. There are also considerable uncertainties related to the efficacy of drug therapy in preventing clinical vertebral fractures, whereas the efficacy for preventing other fractures (relative risk reductions of 20-25%) remains moderate, particularly in terms of the low absolute risk reduction in fractures associated with this treatment. This “Key Symposium” appears in the August issue of Journal of Internal Medicine.Click here to read full-text.
An official ATS/AACN/ACCP/ESICM/SCCM policy statement: responding to requests for potentially inappropriate treatments in Intensive Care Unitsby jmiller on July 16, 2015
“The multisociety statement on responding to requests for potentially inappropriate treatments in intensive care units provides guidance for clinicians to prevent and manage disputes in patients with advanced critical illness.” (Am J Resp Crit Care Med, June 1) Click here to read full-text.
How slow is too slow? Correlation of operative time to complications? An analysis from the Tennessee Surgical Quality Collaborativeby jmiller on July 16, 2015
“Duration of operation correlates with complications and time longer than a statewide established standard carries higher risk. to reduce risk of complications, these data support expeditious surgical technique and preoperative pulmonary training, and offer accurate outcomes assessment for patient counseling based on case duratio. These data can be used directly to counsel individual surgeons to improve outcomes.” (Bull Am Coll Surg, July) Click here to read full-text.
“When analyzed at the county level, the clearest result of mammography screening is the diagnosis of additional small cancers. Furthermore, there is no conocomitant decline in the detection of larger cancers, which might explain the absence of any significant difference in the overall rate of death from the disease. Together, these findings suggest widespread overdiagnosis. As is the case with screening in general, the balance of benefits and harms is likely to be most favorable when screening is directed to those at high risk.” (JAMA Intern Med, early online) Click here to read full-text.
“The FDA has approved edoxaban (Savaysa), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromboembolism (VTE) and for prevention of stroke and systematic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and non-valvular atrial fibrillation.” (Jama, July 7) To read full-text, click here.